Updates are available Correction dated 2023-09-08
Click to view Correction: https://doi.org/10.1038/s43018-023-00646-4
-
Authors
Derrien, Jennifer
Gastineau, Sarah
Frigout, Antoine
Giordano, Nils http://orcid.org/0000-0003-2549-6631
Cherkaoui, Mia http://orcid.org/0000-0001-5488-2238
Gaborit, Victor
Boinon, Rémi
Douillard, Elise
Devic, Magali
Magrangeas, Florence
Moreau, Philippe
Minvielle, Stéphane
Touzeau, Cyrille
Letouzé, Eric http://orcid.org/0000-0002-6369-2839
- License Information
-
More Information
Article History
Received: 23 May 2023
Accepted: 28 July 2023
First Online: 31 August 2023
Change Date: 8 September 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-023-00646-4
Competing interests
: P.M. participates in advisory boards and receives honoraria from pharmaceutical companies producing MM treatments: Janssen, Celgene, Abbvie, Pfizer, Amgen, Sanofi and Takeda. C.T. participates in advisory boards and receives honoraria from Janssen, the company that produces talquetamab. All other authors declare no competing interests.
